Does DEFERASIROX Cause Malignant neoplasm progression? 66 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 66 reports of Malignant neoplasm progression have been filed in association with DEFERASIROX (Deferasirox). This represents 0.6% of all adverse event reports for DEFERASIROX.
66
Reports of Malignant neoplasm progression with DEFERASIROX
0.6%
of all DEFERASIROX reports
49
Deaths
32
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DEFERASIROX?
Of the 66 reports, 49 (74.2%) resulted in death, 32 (48.5%) required hospitalization, and 3 (4.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DEFERASIROX. However, 66 reports have been filed with the FAERS database.
What Other Side Effects Does DEFERASIROX Cause?
Death (1,583)
Diarrhoea (993)
Serum ferritin increased (732)
Haemoglobin decreased (615)
Pyrexia (607)
Malaise (605)
Nausea (603)
Sickle cell anaemia with crisis (570)
Vomiting (520)
Pneumonia (494)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DEFERASIROX Alternatives Have Lower Malignant neoplasm progression Risk?
DEFERASIROX vs DEFERIPRONE
DEFERASIROX vs DEFEROXAMINE
DEFERASIROX vs DEFIBROTIDE
DEFERASIROX vs DEFLAZACORT
DEFERASIROX vs DEGARELIX